Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia

Journal of Clinical Oncology

Volumn 26, Issue 12, 2008, Pages 1932-1939

  Yang, Lei ^a   Panetta, John C ^a   Cai, Xiangjun ^a   Yang, Wenjian ^a   Pei, Deqing ^a   Cheng, Cheng ^a   Kornegay, Nancy ^a   Pui, Ching Hon ^a   Relling, Mary V ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ASPARAGINASE; DEXAMETHASONE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALBUMIN BLOOD LEVEL; ARTICLE; CHILD; CONTROLLED STUDY; DRUG ABSORPTION; FEMALE; HUMAN; HYPOALBUMINEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; TREATMENT OUTCOME; ADOLESCENT; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG HYPERSENSITIVITY; DRUG INTERACTION; INFANT; LYMPHATIC LEUKEMIA; METABOLISM; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; RISK FACTOR;

ADMINISTRATION, ORAL; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; DEXAMETHASONE; DRUG HYPERSENSITIVITY; DRUG INTERACTIONS; FEMALE; HUMANS; INFANT; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK FACTORS;

EID: 42949114872     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.8404     Document Type: Article

References (32)

1. Smyth AC, Wiernik PH: Combination chemotherapy of adult acute lymphocytic leukemia. Clin Pharmacol Ther 19:240-245, 1976
2. Smets LA, Salomons G, van den BJ: Glucocorticoid induced apoptosis in leukemia. Adv Exp Med Biol 457:607-614, 1999
3. Fauci AS, Dale DC, Balow JE: Glucocorticosteroid therapy: Mechanisms of action and clinical considerations. Ann Intern Med 84:304-315, 1976
4. Cassileth PA, Lusk EJ, Torri S, et al: Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy. Arch Intern Med 143:1347-1349, 1983
5. Kris MG, Hesketh PJ, Somerfield MR, et al: American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 24:2932-2947, 2006
6. Cunningham D, Evans C, Gazet JC, et al: Comparison of antiemetic efficacy of domperidone, metoclopramide, and dexamethasone in patients receiving outpatient chemotherapy regimens. Br Med J (Clin Res Ed) 295:250, 1987
7. Mattano LA, Jr., Sather HN, Trigg ME, et al: Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: A report from the Children's Cancer Group. J Clin Oncol 18:3262-3272, 2000
8. Puisset F, Dalenc F, Chatelut E, et al: Dexamethasone as a probe for vinorelbine clearance. Br J Clin Pharmacol 60:45-53, 2005
9. Puisset F, Chatelut E, Dalenc F, et al: Dexamethasone as a probe for docetaxel clearance. Cancer Chemother Pharmacol 54:265-272, 2004
10. Richter O, Ern B, Reinhardt D, et al: Pharmacokinetics of dexamethasone in children. Pediatr Pharmacol 3:329-337, 1983
11. Pui CH, Relling MV, Sandlund JT, et al: Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol 83:S124-S126, 2004 (suppl 1)
12. D'Argenio DZ, Schumitzky A: ADAPT II user's guide. Los Angeles, Biomedical Simulations Resource, USC, 1990
13. Steimer JL, Mallet A, Golmard JL, et al: Alternative approaches to estimation of population pharmacokinetic parameters: Comparison with the nonlinear mixed-effect model. Drug Metab Rev 15:265-292, 1984
14. Xu C, Li CY, Kong AN: Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 28:249-268, 2005
15. Rushmore TH, Kong AN: Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr Drug Metab 3:481-490, 2002
16. Demeule M, Jodoin J, Beaulieu E, et al: Dexamethasone modulation of multidrug transporters in normal tissues. FEBS Lett 442:208-214, 1999
17. Jugert FK, Agarwal R, Kuhn A, et al: Multiple cytochrome P450 isozymes in murine skin: Induction of P450 1A, 2B, 2E, and 3A by dexamethasone. J Invest Dermatol 102:970-975, 1994
18. Hak LJ, Relling MV, Cheng C, et al: Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia 18:1072-1077, 2004
19. Twelves CJ, Dobbs NA, Gillies HC, et al: Doxorubicin pharmacokinetics: The effect of abnormal liver biochemistry tests. Cancer Chemother Pharmacol 42:229-234, 1998
20. Kovarik JM, Sabia HD, Figueiredo J, et al: Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment. Clin Pharmacol Ther 70:425-430, 2001
21. Kovarik JM, Schmouder RL, Hartmann S, et al: Fingolimod (FTY720) in severe hepatic impairment: Pharmacokinetics and relationship to markers of liver function. J Clin Pharmacol 46:149-156, 2006
22. Limdi JK, Hyde GM: Evaluation of abnormal liver function tests. Postgrad Med J 79:307-312, 2003
23. Burke MD: Hepatic function testing. Postgrad Med 64:177-182, 1978
24. Mahl TC: Approach to the patient with abnormal liver tests. Lippincotts Prim Care Pract 2:379-389, 1998
25. Petros WP, Rodman JH, Relling MV, et al: Variability in teniposide plasma protein binding is correlated with serum albumin concentrations. Pharmacotherapy 12:273-277, 1992
26. Burton ME, Show LM, Schentag JJ, et al: Drug metabolism, transport, and the influence of hepatic disease, in Troy D (ed): Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Baltimore, MD, Lippincott Williams & Wilkins, 2005, pp 135-142
27. Woo MH, Hak LJ, Storm MC, et al: Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 12:1527-1533, 1998
28. Wilkinson GR, Shand DG: Commentary: A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390, 1975
29. Crom WR, Glynn-Barnhart AM, Rodman JH, et al: Pharmacokinetics of anticancer drugs in children. Clin Pharmacokinet 12:168-213, 1987
30. Rose JQ, Yurchak AM, Meikle AW, et al: Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics. J Pharmacokinet Biopharm 9:1-14, 1981
31. O'Sullivan BT, Cutler DJ, Hunt GE, et al: Pharmacokinetics of dexamethasone and its relationship to dexamethasone suppression test outcome in depressed patients and healthy control subjects. Biol Psychiatry 41:574-584, 1997
32. Brophy TR, McCafferty J, Tyrer JH, et al: Bioavailability of oral dexamethasone during high dose steroid therapy in neurological patients. Eur J Clin Pharmacol 24:103-108, 1983